Get In Touch

Visceral Pain: Introduction

  • Osteogenesis imperfecta (OI) is a genetic disorder in which the bones fracture (break) easily. Sometimes, the fracture occurs for no known reason. OI can also lead to weak muscles, brittle teeth, a curved spine, and hearing loss. Symptoms of osteogenesis imperfecta can range from mild to severe; it may vary from person to person.
  • OI is caused by one of several genes that aren't working properly. When these genes don't work, they affect the production of collagen, a protein that makes the bones strong.
  • The four types of OI are: Osteogenesis Imperfecta Type I, Osteogenesis Imperfecta Type II, Osteogenesis Imperfecta Type III, and Osteogenesis Imperfecta Type IV. Of these, Osteogenesis type I is highly common and usually the mildest form of OI.

Key Drivers of Global Osteogenesis Imperfecta Treatment Market

  • Increase in number of patients with OI is likely to drive the market during the forecast period. According to National Organization for Rare Disorders, OI type I is estimated to occur in one in 30,000 live births. OI type II is estimated to occur in one in 60,000 live births. The overall prevalence of all types of OI is estimated at .5 per 10,000 individuals in the U.S. Approximately 20,000 to 50,000 individuals in the U.S. have OI.
  • Currently, available treatment options such as physical therapy, bracing, and medication (Bisphosphonates) do not treat the OI condition effectively. Therefore, several researchers are involved in research & development to develop novel therapies and treatment, which is expected to drive the global osteogenesis imperfecta treatment market.
  • Strong product pipeline for osteogenesis imperfecta is likely to boost the market during the forecast period. Currently, Amgen Inc. has one innovative drug product, i.e. Prolia, in phase III for the treatment of OI disease.

Teriparatide segment to expand significantly

  • In terms of drug class, the global osteogenesis imperfecta treatment market can be segregated into teriparatide, denosumab, and others
  • The teriparatide segment accounted for a significant share of the global osteogenesis imperfecta treatment market in 2019. Increase in use of teriparatide drugs in the treatment of OI is likely to propel the segment during the forecast period.

Oral to be highly lucrative segment

  • Based on route of administration, the global osteogenesis imperfecta treatment market can be classified into parenteral, oral, and others
  • The oral segment accounted for a significant share of the global market, in terms of revenue, in 2019. The trend is likely to continue during the forecast period. Most products can be administered through the oral route, which is likely to boost the segment.

Hospitals pharmacies to be highly promising segment

  • Based on distribution channel, the global osteogenesis imperfecta treatment market can be classified into hospital pharmacies, retail pharmacies, and online sales
  • The hospital pharmacies segment accounted for a prominent share of the market, in terms of revenue, in 2019. The segment is anticipated to expand during the forecast period as most major products are prescription products that are available at hospital pharmacies.

North America to Dominate Global Osteogenesis Imperfecta Treatment Market

  • In terms of region, the global osteogenesis imperfecta treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America dominated the global osteogenesis imperfecta treatment market in 2019. The trend is projected to continue during the forecast period. The region’s dominance can be attributed to the presence of major market players and increase in focus on research and development activity in the region.
  • The osteogenesis imperfecta treatment market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period owing to an increase in adoption of new products and a rise in number of patients suffering from osteogenesis imperfecta.

Key Players Operating in Global Osteogenesis Imperfecta Treatment Market

The global osteogenesis imperfecta treatment market was highly fragmented in 2019. Key players operating in the global market are:

  • Bone Therapeutics SA
  • Mereo BioPharma Group plc
  • Celgene Corporation
  • Eli Lilly and Company
  • Cipla Inc.
  • Amgen Inc
  • Sun Pharmaceutical Industries Limited
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd
  • Merck & Co., Inc.

Global Osteogenesis Imperfecta Treatment Market: Research Scope

  • Osteogenesis Imperfecta Treatment Market, by Drug Class
  • Teriparatide
  • Denosumab
  • Others

Global Osteogenesis Imperfecta Treatment Market, by Route of Administration

  • Oral
  • Parenteral
  • Others

Global Osteogenesis Imperfecta Treatment Market, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Sales

Global Osteogenesis Imperfecta Treatment Market, by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Osteogenesis Imperfecta Treatment Market